Olivier Brandicourt
   HOME

TheInfoList



OR:

Olivier Brandicourt (born 13 February 1956) is a French business executive and physician, and the former
chief executive officer A chief executive officer (CEO), also known as a central executive officer (CEO), chief administrator officer (CAO) or just chief executive (CE), is one of a number of corporate executives charged with the management of an organization especial ...
of
Sanofi Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Syn ...
.


Career

Olivier Brandicourt studied medicine in Paris and specialized in infectious diseases and tropical medicine. He spent eight years with the Institute of Infectious and Tropical Diseases of the
Pitié-Salpêtrière Hospital Pitié-Salpêtrière University Hospital (french: Hôpital universitaire la Pitié-Salpêtrière, ) is a teaching hospital in the 13th arrondissement of Paris. Part of the and a teaching hospital of Sorbonne University. History The Salpêtrià ...
in Paris, where he focused on malaria research in West and Central Africa. Prior to that, he spent two years in the Republic of the Congo as a doctor. He holds an Advanced Degree in Cellular and Immunological Pathophysiology ( Paris Descartes University) and a master's degree in Biology ( University of Paris XII). Olivier Brandicourt was appointed CEO of Sanofi in February 2015. Before that, between 2013 and 2015, he was chief executive officer and chairman of the board of management of Bayer HealthCare AG, where he was responsible for leading the company's healthcare portfolio globally, encompassing pharmaceuticals, consumer care, animal health and medical care businesses.Bayer HealthCare
Executive Committee
February 25, 2015
Brandicourt joined Pfizer in 2000, after its acquisition of Warner-Lambert/
Parke-Davis Parke-Davis is a subsidiary of the pharmaceutical company Pfizer. Although Parke, Davis & Co. is no longer an independent corporation, it was once America's oldest and largest drug maker, and played an important role in medical history. In 1970 ...
, where he started his career, first in Medical Affairs and later in Marketing and Management. He spent 12 years at Pfizer Inc. where he held several senior positions across a range of disciplines, including President and General Manager of the Global Specialty Care and Primary Care businesses, and later as President and General Manager of the Primary Care Business Unit. He served as a member of the executive leadership team of
Pfizer Pfizer Inc. ( ) is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The company was established in 1849 in New York by two German entrepreneurs, Charles Pfizer ...
Inc. and oversaw the introduction of the cholesterol treatment Lipitor.Bloomberg
Executive Profile
February 25, 2015
In 2007, he was the supervisor of the failed launch of the Exubera. In February 2015, Olivier Brandicourt was appointed as the chief executive officer of
Sanofi Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Syn ...
.Noemie Bisserbe
Sanofi Names Olivier Brandicourt CEO
''
The Wall Street Journal ''The Wall Street Journal'' is an American business-focused, international daily newspaper based in New York City, with international editions also available in Chinese and Japanese. The ''Journal'', along with its Asian editions, is published ...
'', February 20, 2015
Andrew Ward
Five big challenges facing Sanofi’s new chief Olivier Brandicourt
''Financial Times'', 15 February 2015
His golden handshake of US$4.5 million upon taking on the appointment was criticized by French Ministers Stéphane Le Foll and
Ségolène Royal Marie-Ségolène Royal (; born 22 September 1953) is a French politician who was the Socialist Party candidate for the Presidency of France in the 2007 election. Royal was president of the Poitou-Charentes Regional Council from 2004 to 201 ...
.Ed Silverman
French Government Slams Sanofi Over Brandicourt Pay Package
''The Wall Street Journal'', 24 February 2015
In November 2015, Sanofi announced its 2020 Strategic Plan that implies reshaping its activities into 3 portfolios: Diabetes, cardiovascular, and vaccines. In May 2016, Olivier Brandicourt announced a reshuffle in the company's management, in line with the 2020 Strategic Plan. In January 2017, Sanofi completed an asset swap of its animal health business, Merial, for Boehringer's consumer healthcare business, CHC. Subsequently, Sanofi launched a fifth Global Business Unit for Consumer Health Care.


Other tenures

* Member of the council of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA),Bayer
Subgroup Management Boards
February 25, 2015
* Member of the Board of Management of the
Pharmaceutical Research and Manufacturers of America Pharmaceutical Research and Manufacturers of America (PhRMA, pronounced ), formerly known as the Pharmaceutical Manufacturers Association, is a trade group representing companies in the pharmaceutical industry in the United States. Founded in 195 ...
(PhRMA).PhRMA
PhRMA Leadership
February 25, 2015
* Vice-President of the European Federation of Pharmaceutical Industries and Associations (EFPIA); * Honorary Fellow of the Royal College of Physicians in London * Trustee of the Children's Aid Society in New York.The Children's Aid Society
Executive Staff & Trustees
February 25, 2015


References

{{DEFAULTSORT:Brandicourt, Olivier 1956 births Living people French businesspeople French healthcare chief executives French tropical physicians Pfizer people Sanofi people Bayer people People from Casablanca